Top

Published in:

07-07-2023 | Breast Cancer | Research

CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer

Authors: Peiwei Yang, Fan Yu, Zheng Yao, Xu Ding, Hanmei Xu, Juan Zhang

Published in: Cancer Immunology, Immunotherapy | Issue 10/2023

Abstract

Triple negative breast cancer (TNBC) is a subtype of breast cancer with the highest degree of malignancy and the worst prognosis. The application of immunotherapy for TNBC is limited. This study was to verify the potential application of chimeric antigen receptor-T cells (CAR-T cells) targeting CD24 named as 24BBz in treatment of TNBC. 24BBz was constructed by lentivirus infection and then was co-culture with breast cancer cell lines to evaluate the activation, proliferation and cytotoxicity of engineered T cells. The anti-tumor activity of 24BBz was verified in the subcutaneous xenograft model of nude mice. We found that CD24 gene was significantly up-regulated in breast cancer (BRCA), especially in TNBC. 24BBz showed antigen-specific activation and dose-dependent cytotoxicity against CD24-positive BRCA tumor cells in vitro. Furthermore, 24BBz showed significant anti-tumor effect in CD24-positive TNBC xenografts and T cells infiltration in tumor tissues, while some T cells exhibited exhaustion. No pathological damage of major organs was found during the treatment. This study proved that CD24-specific CAR-T cells have potent anti-tumor activity and potential application value in treatment of TNBC.

Available only for authorised users

Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G (2021) Breast cancer. Lancet (London, England) 397(10286):1750–1769. https://doi.org/10.1016/s0140-6736(20)32381-3CrossRefPubMed

Bianchini G, De Angelis C, Licata L, Gianni L (2022) Treatment landscape of triple-negative breast cancer-expanded options, evolving needs. Nat Rev Clin Oncol 19(2):91–113. https://doi.org/10.1038/s41571-021-00565-2CrossRefPubMed

Hua Z, White J, Zhou J (2022) Cancer stem cells in TNBC. Semin Cancer Biol 82:26–34. https://doi.org/10.1016/j.semcancer.2021.06.015CrossRefPubMed

Garrido-Castro AC, Lin NU, Polyak K (2019) Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov 9(2):176–198. https://doi.org/10.1158/2159-8290.Cd-18-1177CrossRefPubMedPubMedCentral

He MY et al (2018) Radiotherapy in triple-negative breast cancer: current situation and upcoming strategies. Crit Rev Oncol Hematol 131:96–101. https://doi.org/10.1016/j.critrevonc.2018.09.004CrossRefPubMed

Nedeljković M, Damjanović A (2019) Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge. Cells. https://doi.org/10.3390/cells8090957CrossRefPubMedPubMedCentral

Jabbarzadeh Kaboli P et al (2022) Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates. Am J Cancer Res 12(4):1671–1685PubMedPubMedCentral

Kristiansen G et al (2003) CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 9(13):4906–4913PubMed

Pirruccello SJ, LeBien TW (1986) The human B cell-associated antigen CD24 is a single chain sialoglycoprotein. J Immunol (Baltimore, md.: 1950) 136(10):3779–3784CrossRef

10.

Tarhriz V et al (2019) Overview of CD24 as a new molecular marker in ovarian cancer. J Cell Physiol 234(3):2134–2142. https://doi.org/10.1002/jcp.27581CrossRefPubMed

11.

Barkal AA et al (2019) CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature 572(7769):392–396. https://doi.org/10.1038/s41586-019-1456-0CrossRefPubMedPubMedCentral

12.

Baumann P et al (2012) CD24 interacts with and promotes the activity of c-src within lipid rafts in breast cancer cells, thereby increasing integrin-dependent adhesion. Cell Mol Life Sci 69(3):435–448. https://doi.org/10.1007/s00018-011-0756-9CrossRefPubMed

13.

Kwon MJ et al (2015) CD24 overexpression is associated with poor prognosis in luminal a and triple-negative breast cancer. PLoS ONE 10(10):e0139112. https://doi.org/10.1371/journal.pone.0139112CrossRefPubMedPubMedCentral

14.

Chan SH et al (2019) Identification of the novel role of CD24 as an oncogenesis regulator and therapeutic target for triple-negative breast cancer. Mol Cancer Ther 18(1):147–161. https://doi.org/10.1158/1535-7163.Mct-18-0292CrossRefPubMed

15.

Deng X et al (2017) CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer. Oncotarget 8(24):38294–38308. https://doi.org/10.18632/oncotarget.16203CrossRefPubMedPubMedCentral

16.

Jing X et al (2018) CD24 is a potential biomarker for prognosis in human breast carcinoma. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 48(1):111–119. https://doi.org/10.1159/000491667CrossRef

17.

Maliar A et al (2012) Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology 143(5):1375-1384.e1375. https://doi.org/10.1053/j.gastro.2012.07.017CrossRefPubMed

18.

Sun F et al (2021) Bispecific CAR-T cells targeting both BCMA and CD24: a potentially treatment approach for multiple myeloma. Blood 138:2802CrossRef

19.

Sun F et al (2017) Engineering a high-affinity humanized anti-CD24 antibody to target hepatocellular carcinoma by a novel CDR grafting design. Oncotarget 8(31):51238–51252. https://doi.org/10.18632/oncotarget.17228CrossRefPubMedPubMedCentral

20.

Jayaraman J et al (2020) CAR-T design: elements and their synergistic function. EBioMedicine 58:102931. https://doi.org/10.1016/j.ebiom.2020.102931CrossRefPubMedPubMedCentral

21.

Xu N et al (2021) STING agonist promotes CAR T cell trafficking and persistence in breast cancer. J Exp Med. https://doi.org/10.1084/jem.20200844CrossRefPubMedPubMedCentral

22.

Liedtke C et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275–1281. https://doi.org/10.1200/jco.2007.14.4147CrossRefPubMed

23.

Zhao Z, Chen Y, Francisco NM, Zhang Y, Wu M (2018) The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sin B 8(4):539–551. https://doi.org/10.1016/j.apsb.2018.03.001CrossRefPubMedPubMedCentral

24.

Xia L et al (2020) EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both in vitro and in vivo. Clin Transl Immunol 9(5):e01135. https://doi.org/10.1002/cti2.1135CrossRef

25.

Corti C et al (2022) CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress. Expert Opin Investig Drugs 31(6):593–605. https://doi.org/10.1080/13543784.2022.2054326CrossRefPubMed

26.

Tchou J et al (2017) Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer. Cancer Immunol Res 5(12):1152–1161. https://doi.org/10.1158/2326-6066.Cir-17-0189CrossRefPubMedPubMedCentral

27.

Yamashita N et al (2021) MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor. J Immunother Cancer 9:1CrossRef

28.

Wei J et al (2018) A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects. Cell Immunol 331:49–58CrossRefPubMed

29.

Chen H et al (2021) CD27 enhances the killing effect of CAR T cells targeting trophoblast cell. Cancer Immunol Immunother 70:2059–2071CrossRefPubMed

30.

Yang XR et al (2009) CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. Clin Cancer Res 15(17):5518–5527. https://doi.org/10.1158/1078-0432.Ccr-09-0151CrossRefPubMed

31.

He H et al (2015) A novel antibody targeting CD24 and hepatocellular carcinoma in vivo by near-infrared fluorescence imaging. Immunobiology 220(12):1328–1336. https://doi.org/10.1016/j.imbio.2015.07.010CrossRefPubMed

32.

Maus MV et al (2013) T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 1:26–31CrossRefPubMedPubMedCentral

33.

Lv J et al (2019) Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. J Hematol Oncol 12(1):18. https://doi.org/10.1186/s13045-019-0704-yCrossRefPubMedPubMedCentral

34.

Cherkassky L, Hou Z, Amador-Molina A, Adusumilli PS (2022) Regional CAR T cell therapy: an ignition key for systemic immunity in solid tumors. Cancer Cell 40(6):569–574. https://doi.org/10.1016/j.ccell.2022.04.006CrossRefPubMedPubMedCentral

35.

Adusumilli PS et al (2014) Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med 6(261):261151. https://doi.org/10.1126/scitranslmed.3010162CrossRef

36.

Hou AJ, Chen LC, Chen YY (2021) Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discov 20(7):531–550. https://doi.org/10.1038/s41573-021-00189-2CrossRefPubMed

37.

Sun C, Mezzadra R, Schumacher TN (2018) Regulation and function of the PD-L1 checkpoint. Immunity 48(3):434–452. https://doi.org/10.1016/j.immuni.2018.03.014CrossRefPubMedPubMedCentral

38.

Cherkassky L et al (2016) Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest 126(8):3130–3144. https://doi.org/10.1172/jci83092CrossRefPubMedPubMedCentral

39.

Grosser R, Cherkassky L, Chintala N, Adusumilli PS (2019) Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell 36(5):471–482. https://doi.org/10.1016/j.ccell.2019.09.006CrossRefPubMedPubMedCentral

40.

Rafiq S et al (2018) Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol 36(9):847–856. https://doi.org/10.1038/nbt.4195CrossRefPubMedPubMedCentral

41.

Choi BD et al (2019) CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J Immunother Cancer 7(1):304. https://doi.org/10.1186/s40425-019-0806-7CrossRefPubMedPubMedCentral

42.

Yu S, Yi M, Qin S, Wu K (2019) Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol Cancer 18(1):125. https://doi.org/10.1186/s12943-019-1057-4CrossRefPubMedPubMedCentral

43.

Rafiq S, Hackett CS, Brentjens RJ (2020) Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol 17(3):147–167. https://doi.org/10.1038/s41571-019-0297-yCrossRefPubMed

44.

Paszkiewicz PJ et al (2016) Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. J Clin Invest 126(11):4262–4272. https://doi.org/10.1172/jci84813CrossRefPubMedPubMedCentral

Title: CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer
Authors: Peiwei Yang
Fan Yu
Zheng Yao
Xu Ding
Hanmei Xu
Juan Zhang
Publication date: 07-07-2023
Publisher: Springer Berlin Heidelberg
Keywords: Breast Cancer
Breast Cancer
Solid Tumor
Published in: Cancer Immunology, Immunotherapy / Issue 10/2023
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-023-03491-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2023

Circadian pattern subtyping unveiling distinct immune landscapes in breast cancer patients for better immunotherapy

Melanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular traps

Revealing the impact of CD70 expression on the manufacture and functions of CAR-70 T-cells based on single-cell transcriptomics

Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastoma

Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment

Immune checkpoint inhibitor treatment of brain metastasis associated with a less invasive growth pattern, higher T-cell infiltration and raised tumor ADC on diffusion weighted MRI

Keynote webinar | Spotlight on antibody–drug conjugates in cancer